Fio is a cheminformatics scientist in the drug discovery team focusing on supporting the design and generation of massive datasets to enable machine learning driven drug discovery.
She obtained her Ph.D. in theoretical chemistry at the laboratory of cheminformatics in Strasbourg. Afterwards, she joined the Computer-Aided Drug Design team at Novartis Institutes for BioMedical Research as a postdoctoral scholar. Following that, she worked at DiCE Molecules, a DNA-encoded library start-up.
Fio enjoys running and hiking in the beautiful redwood forests and is passionate about arts and crafts.
As Senior Vice-President of Drug Discovery, Keith is responsible for machine learning-enabled drug discovery programs at insitro. Keith and his team are both establishing new drug design capabilities, exploiting the power of machine learning models, and undertaking drug discovery programs on molecular targets derived via the insitro-human (ISH) target discovery platform.
Keith has over three decades of drug discovery experience, building and leading research enterprises ranging from handfuls to hundreds of scientists, tackling programs across a wide range of therapeutic areas, and employing a panoply of therapeutic modalities. During his career, Keith, and the organizations he has led, have delivered over thirty clinical candidates, across fifteen therapeutic areas, many of which have reached Phase 2, and two of which are in the hands of physicians treating patients today – eletriptan (Relpax®) for migraines and maraviroc (Selzentry®) for HIV infections.
Before joining insitro, Keith was President of the Ferring Research Institute in San Diego, engaged in the discovery of peptide therapeutics. Before joining Ferring, Keith had a long career at Pfizer, leading discovery research at three different sites across the US and UK, heading the company’s R&D strategy team, and running a laboratory as a visiting investigator at The Scripps Research Institute.
Keith completed his academic and postdoctoral studies at Imperial College London, The University of Cambridge (Raphael lab), Stanford University (Johnson lab), and Columbia University (Stork lab).
In his free time, Keith enjoys cycling, jogging, reading, writing and mechanical watches.